Loading...
XNASCLLS
Market cap112mUSD
Dec 24, Last price  
1.56USD
1D
-0.76%
1Q
-27.78%
Jan 2017
-90.80%
IPO
-96.03%
Name

Cellectis SA

Chart & Performance

D1W1MN
XNAS:CLLS chart
P/E
—
P/S
148.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.93%
Rev. gr., 5y
-43.16%
Revenues
755k
-96.06%
4,101,36014,770,16417,319,04420,980,18320,728,40327,814,95422,816,15026,298,70155,043,40442,584,45125,188,00012,731,00015,190,00073,949,00073,949,00019,171,000755,000
Net income
-101m
L+2.40%
0185,1490000024,32000-99,368,000-78,693,000-90,686,000-72,571,000-86,280,000-98,688,000-101,059,000
CFO
-25m
L-71.70%
01,779,1010000050,738,1193,537,9260-52,327,000-68,137,000-69,142,000-80,262,000-104,562,000-87,444,000-24,746,000
Earnings
Apr 28, 2025

Profile

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
URL
https://www.cellectis.com/
IPO date
Feb 06, 2007
Employees
231
Domiciled in
FR
Incorporated in
FR

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
755
-96.06%
19,171
-74.08%
73,949
0.00%
Cost of revenue
105,195
119,875
167,426
Unusual Expense (Income)
NOPBT
(104,440)
(100,704)
(93,477)
NOPBT Margin
Operating Taxes
(6,211)
87
(11,203)
Tax Rate
NOPAT
(98,229)
(100,791)
(82,274)
Net income
(101,059)
2.40%
(98,688)
14.38%
(86,280)
18.89%
Dividends
Dividend yield
Proceeds from repurchase of equity
67,936
(1,138)
48,517
BB yield
-38.69%
1.19%
-13.33%
Debt
Debt current
13,664
12,960
10,683
Long-term debt
122,842
127,119
171,411
Deferred revenue
Other long-term liabilities
22,881
2,391
4,698
Net debt
(75,162)
33,591
(10,565)
Cash flow
Cash from operating activities
(24,746)
(87,444)
(104,562)
CAPEX
(1,073)
(2,441)
(19,743)
Cash from investing activities
(15,510)
(2,761)
7,279
Cash from financing activities
82,865
1,145
47,525
FCF
(83,074)
(59,789)
(83,850)
Balance
Cash
203,815
97,697
186,135
Long term investments
7,853
8,791
6,524
Excess cash
211,630
105,529
188,962
Stockholders' equity
(438,091)
(457,181)
(698,221)
Invested Capital
630,723
665,304
1,041,561
ROIC
ROCE
EV
Common stock shares outstanding
57,013
45,547
44,820
Price
3.08
46.67%
2.10
-74.14%
8.12
-69.99%
Market cap
175,599
83.59%
95,649
-73.72%
363,941
-68.36%
EV
100,437
137,213
368,557
EBITDA
(85,917)
(82,269)
(76,907)
EV/EBITDA
Interest
6,428
3,787
5,338
Interest/NOPBT